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ABSTRACT
Motivation: A two-stage association study is the most commonly
used method among multistage designs to efﬁciently identify disease
susceptibility genes. Recently, some SNP studies have utilized more
than two stages to detect disease genes. However, there are few
available programs for calculating statistical powers and positive
predictive values (PPVs) of arbitrary n-stage designs.
Results: We developed programs for a multistage case–control
association study using R language. In our programs, input
parametersincludenumbersofsamplesandcandidateloci,genome-
wide false positive rate and proportions of samples and loci to be
selected at the k-th stage (k =1,…,n). The programs output statistical
powers, PPVs and numbers of typings in arbitrary n-stage designs.
The programs can contribute to prior simulations under various
conditions in planning a genome-wide association study.
Availability: The R programs are freely available for academic users
and can be downloaded from
http://www.med.niigata-u.ac.jp/eng/resources/informatics/gwa.html
Contact: nktmr@m12.alpha-net.ne.jp
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
Genome-wide association (GWA) case–control studies using
genetic polymorphism data, including data on single nucleotide
polymorphisms (SNPs) and microsatellite markers, aim to identify
genes involved in common human diseases. Some multistage GWA
case–control studies have been proposed as powerful and cost-
effective study designs. The most commonly used method among
the multistage designs is a two-stage design. In the designs, all
markers in the ﬁrst stage are genotyped and statistical tests are
conducted for each marker. Only signiﬁcant markers selected in the
ﬁrststageremainforthefollowingstages.Attheendofthelaststage,
∗To whom correspondence should be addressed.
theoverallevidenceforassociationisevaluatedbyreplication-based
analysis (RBA) (Satagopan et al., 2002) or joint analysis (JA) (Skol
et al., 2006).
Recently, some SNP-based studies have utilized more than two
stages of multistage designs (Kathiresan et al., 2007; Prentice et al.,
2006). However, there are few available programs for multistage
designs. Skol et al. (2006) proposed JA by new statistics of a
linear combination weighted by the square root of the proportion
of subjects and presented their power calculation for one- and two-
stagedesignsontheirwebsite,buttheyhavenotreportedaboutmore
than two stages. In previous studies, statistical power was used to
evaluate the performance of different designs. On the other hand,
positive predictive values (PPVs) are more practical for identifying
disease susceptibility genes implicated in complex traits. However,
there is no program for statistical powers, PPVs and numbers of
typings of multistage designs for arbitrary n>2.
In this article, we present programs for calculating the indicators
of arbitrary n-stage designs using disease model parameters
(prevalence, disease-associated allele frequency and genetic relative
risk) or 2×3 contingency table data as input parameters by R
language (Crawley, 2005). The programs can output the indicators
for allelic models, additive models, dominant models and recessive
models under various conditions.
2 METHODS
2.1 Statistical background for detecting risk SNPs
We extended Skol’s power-evaluation methods of two-stage designs (Skol
et al., 2006) to generalized n-multistage designs (n being an arbitrary natural
number). Let πs,k be a proportion of the sample size at the k-th stage and let
πm,k be a proportion of loci to be selected at the k-th stage (k =1,…,n). In
RBA, statistical tests are conducted by statistics for difference in ratio of an
expected disease-associated allele rate in cases (p ) and that in controls (p).
Criticalvaluesforthek-thstageofRBA(Cr,k)canbeobtainedbycalculating
 −1
1−πm,k/2

under the null hypothesis, and powers of k-stage designs
of RBAare calculated by multiplying cumulative distribution functions of a
normal distribution of each stage under the alternative hypothesis.
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Test statistics of JAare represented as the√πs,k-weighted sum of statistics
of each stage. Since the statistics of JA and those of previous stages are
not independent from those deﬁnitions, critical values of JA (Cj,k) can be
calculated iteratively by solving the equation of n-multiple integrals under
the null hypothesis using the Newton–Raphson method. Powers of JA can
be calculated with Cj,k under the alternative hypothesis.
PPVs can be calculated by the number of true positive loci (tpk) and false
positive loci (fpk). Let N be the number of samples in cases and controls, M
be the number of candidate loci and m be the number of true loci. tpk is given
as m×power of RBA or JA, and fpk is given as

M−m

×
n
k=1πm,k.
Therefore, PPV at the k-th stage is calculated as tpk

tpk+fpk

.
The number of typings of one-stage design is given as 2MN.
The number of typings of n-stage design is
2MNπs,1+
n 
k=2

2MNπs,k
k−1 	
l=1
πm,l



n2

.
2.2 Algorithm and programs for multistage designs
ThealgorithmforthepowersandPPVsandnumbersoftypingsofmultistage
designs consists of the following three modules: a module for internal
parameters, a module for RBA and a module for JA.
Let a candidate locus be a base pair of allele A and allele a and let a
penetrance of aa be f0. The relative risk to f0 in a human population of Aa
and that of AA will be f1/f0 and f2/f0, respectively. By using disease model
parameters, such as prevalence (Prev) and disease-associated allele rate (ppo)
as input parameters, f0, f1 and f2 in the allelic model, in which the numbers
of each allele per cases and controls are counted, is calculated as follows:
f0=
Prev
p2
po×

f2

f0

+2×ppo×

1−ppo

×

f1

f0

+

1−ppo
2 ,
f1
f0
=
f2
f1
=GRR (genotype relative risk),
f2
f0
=

f1
f0
2
=GRR2.
Therefore, p  and p are calculated as follows:
p =
p2
po×f2+ppo×

1−ppo

×f1
Prev
,
p=
p2
po×

1−f2

+ppo×

1−ppo

×

1−f1


1−Prev
 .
In additive models, dominant models and recessive models, those genotype
rates in cases and controls are calculated according to each deﬁnition (refer
to Supplementary Material).
The programs for calculating the indicators were made by using R
language (version 2.7.1). In the program, calculation of the equation of
n-multiple integrals uses the ‘pmvnorm’ function. This function computes
the distribution function of the multivariate normal distribution for arbitrary
limits and correlation matrices based on algorithms by Genz (1992). We
prepared the R package and the web user interface (WUI) for calculating
them in our website (see Availability).
2.3 Simulation algorithm
Assume the following conditions for calculating the powers and PPVs and
the numbers of typings in one- to ﬁve-stage designs: N =1000, M =500000,
m=5, genome-wide false positive rate (αgenome)=0.05 and odds ratio
(OR)=1.5, which is calculated by Prev=0.1, disease-associated allele
frequency=0.4 and GRR=1.44, and the genetic model is set to be an allelic
model. The samples were equally divided into each stage. In addition, πm,k
are set to equal proportions to adjust the product of them to 0.0001 so that
the number of remaining loci in the ﬁnal stage by each stage design is equal.
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Fig. 1. Powers and PPVs and numbers of typings by RBA and JA in one-
to ﬁve-stage designs.
3 RESULTS
Figure 1 shows the powers and PPVs and the numbers of typings
of RBA and JA in one- to ﬁve-stage designs. The powers of JA
were always higher than those of RBA. In RBA, with an increase
in the number of stages, the numbers of typings and the powers
monotonically decreased. However, in JA, the powers decreased
more slowly than in RBA. The powers of the three-stage design
were higher than the powers of two-, four- and ﬁve-stage designs.
On the other hand, PPVs of RBA and those of JA both exhibited
plateau behaviors in a high range of PPVs.
4 DISCUSSION
Multistage case–control association designs have the distinct
advantage of considerable reduction in the number of typings,
while maintaining high powers for many practical projects to detect
disease-related genes.
We made programs for multistage designs by an arbitrary number
ofstagesbyusingpackageRlanguage.Inthisstudy,thepropertiesof
multistagedesignsofRBAandJAwereinvestigatedbycomparisons
of one- to ﬁve-stage designs, and it was shown that the powers by
JA are larger than those by RBA in any number of stages and that
three-stage designs are superior to two-, four- and ﬁve-stage designs
in powers under the condition that the samples are equally divided
into each stage (refer to Supplementary Material).
Factors affecting powers include N, M, πs,k, πm,k and study
designs. However, there is no simple way to predict the powers by
various study designs. Therefore, our programs would be beneﬁcial
in study communities at the planning stage of GWA studies.
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